Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1998-2004
Published online before print June 23, 2005, doi: 10.1161/01.ATV.0000174798.25085.d6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/9/1998    most recent
01.ATV.0000174798.25085.d6v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsiao, G.
Right arrow Articles by Sheu, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsiao, G.
Right arrow Articles by Sheu, J. R.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1998.)
© 2005 American Heart Association, Inc.


Thrombosis

Protective Mechanisms of Inosine in Platelet Activation and Cerebral Ischemic Damage

George Hsiao; Kuang H. Lin; Yi Chang; Ta L. Chen; Nien H. Tzu; Duen S. Chou; Joen R. Sheu

From the Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan.

Correspondence to Dr Joen-Rong Sheu, Graduate Institute of Medical Sciences, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 110, Taiwan. E-mail sheujr{at}tmu.edu.tw

Objective— Inosine is a naturally occurring nucleoside degraded from adenosine. Recent studies have demonstrated that inosine has potent immunomodulatory and neuroprotective effects. In the present study, we further investigated the inhibitory effects of inosine on platelet activation in vitro and in vivo, as well as in attenuating middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia in rats.

Methods and Results— Inosine concentration-dependently (0.5 to 6.0 mmol/L) inhibited platelet aggregation stimulated by agonists. Inosine (1.5 and 3.0 mmol/L) inhibited phosphoinositide breakdown, [Ca+2]i, and TxA2 formation in human platelets stimulated by collagen (1 µg/mL). In addition, inosine (1.5 and 3.0 mmol/L) markedly increased levels of cyclic guanylate monophosphate (GMP) and cyclic GMP-induced vasodilator-stimulated phosphoprotein Ser157 phosphorylation. Rapid phosphorylation of a platelet protein of molecular weight 47 000 (P47), a marker of protein kinase C activation, was triggered by collagen (1 µg/mL). This phosphorylation was markedly inhibited by inosine (3.0 mmol/L). Inosine (1.5 and 3.0 mmol/L) markedly reduced hydroxyl radical in collagen (1 µg/mL)-activated platelets. In in vivo studies, inosine (400 mg/kg) significantly prolonged the latency period of inducing platelet plug formation in mesenteric venules of mice, and administration of 2 doses (100 mg/kg) or a single dose (150 mg/kg) of inosine significantly attenuated MCAO-induced focal cerebral ischemia in rats.

Conclusions— Platelet aggregation contributes significantly to MCAO-induced focal cerebral ischemia. The most important findings of this study suggest that inosine markedly inhibited platelet activation in vitro and in vivo, as well as cerebral ischemia. Thus, inosine treatment may represent a novel approach to lowering the risk of or improving function in thromboembolic-related disorders and ischemia-reperfusion brain injury.

Inosine inhibited platelet aggregation, phosphoinositide breakdown, [Ca+2]i, PKC activation, TxA2, and hydroxyl radical formation stimulated by collagen. Inosine increased levels of cyclic GMP-induced VASP Ser157 phosphorylation. Inosine inhibited platelet plug formation and attenuated focal cerebral ischemia in vivo. Thus, inosine treatment may represent a novel approach to lowering the risk of thromboembolic-related disorders.


Key Words: inosine • middle cerebral artery occlusion • platelet activation • protein kinase C • vasodilator-stimulated phosphoprotein




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. Hsiao, J. J. Lee, K. H. Lin, C. H. Shen, T. H. Fong, D. S. Chou, and J. R. Sheu
Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: In vitro and in vivo studies
Cardiovasc Res, September 1, 2007; 75(4): 782 - 792.
[Abstract] [Full Text] [PDF]